Literature DB >> 18299669

Lichen planus and hepatitis C virus infection: an updated critical review.

M Carrozzo1, R Pellicano.   

Abstract

An association between lichen planus (LP) and liver diseases has been reported. PubMed database has been used to extract information on hepatitis C virus (HCV) infection and LP. The results suggest that LP, mainly the oral type, is significantly associated with HCV infection in Southern Europe and Japan but not in Northern Europe. These differences may be related to genetic factors. Detection of HCV viral sequences and HCV-specific CD4+ and/or CD8+ T lymphocytes in oral samples of LP patients suggests that HCV might be involved in the development of oral lesions via an immunological pathway, characterized by an excessive production of Th1 cytokines following an uneffective antiviral immuno-response.

Entities:  

Mesh:

Year:  2008        PMID: 18299669

Source DB:  PubMed          Journal:  Minerva Gastroenterol Dietol        ISSN: 1121-421X


  5 in total

1.  No association of oral lichen planus and hepatitis C virus infection in central Germany.

Authors:  Torsten W Remmerbach; Jan Liese; Sarah Krause; Ingolf Schiefke; Franziska Schiefke; Melanie Maier; Uwe G Liebert
Journal:  Clin Oral Investig       Date:  2015-09-28       Impact factor: 3.573

2.  [Vulvar diseases].

Authors:  M Peckruhn; P Elsner
Journal:  Hautarzt       Date:  2015-01       Impact factor: 0.751

3.  Bilateral Linear Lichen Planus Pigmentosus Associated with Hepatitis C Virus Infection.

Authors:  Vasanop Vachiramon; Poonkiat Suchonwanit; Kunlawat Thadanipon
Journal:  Case Rep Dermatol       Date:  2010-09-11

Review 4.  Systemic abnormalities in liver disease.

Authors:  Masami Minemura; Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2009-06-28       Impact factor: 5.742

5.  Expression of human DNA mismatch-repair protein, hMSH2, in patients with oral lichen planus.

Authors:  Hao-Bo Li; Ying-Huai Zhang; Hui-Zhen Chen; Yong Chen
Journal:  Exp Ther Med       Date:  2014-11-06       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.